All studies
Gastroenterology · Claims + National Database · US, France
Kirchgesner 2021
Crohn's disease
Not definedSuperiorityAcademia2/5 disclosures
Comparisons
1
In the analysis
0
1 withheld
Target trials
1
Emulations reported
3
2 treatments
Design and methods
- Estimand
- Not defined
- Design hypothesis
- Superiority
- Matching / weighting
- 1:1 PS matching
- Analysis method
- Log-binomial regression
- Missing data
- Complete case
- Covariates adjusted
- 27
- DAG
- No
- QBA
- No
Data and sample
- Data type
- Claims + National Database
- Data sources
- 3
- Geography
- US, France
- Eligible sample
- 15007
- Treated
- 1437
- Control
- 1437
- Emulations
- 3
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Conference abstract
- https://dx.doi.org/10.1002/pds.5305
- Data availability
- Unavailable
- Code availability
- Unavailable
- Conflicts of interest
- Declared: Industry
- COI institutions
- Roche, Pfizer, Janssen, Allergan, AbbVie, Merck Sharp & Dohme, Ferring Pharmaceuticals, Mayoly-Spendler, Takeda, Tillots, Abbott, Hospira-Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb
- Funding
- Declared: Research institute
- Funders
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2021_Kirchgesner_CrohnsDisease
- DOI
- https://doi.org/10.1002/cpt.2304
- Affiliations
- Harvard Medical School, Sorbonne Université
- Sector
- Academia
- Target trials (study level)
- SONIC
- Registration
- NCT00094458